Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.51 |
| ▸ | PI4KA | P42356 | 8/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 8/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 8/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577456 | 0.82 | ADORA2A (0.56) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL17060219 | 0.76 | ADORA2A (0.37) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL4412912 | 0.76 | ADORA2A (0.49) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL29400753 | 0.75 | ADORA2A (0.66) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL42314 | 0.75 | ADORA2A (0.66) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL669407 | 0.75 | PI4KA (0.56) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL30109321 | 0.73 | NUDT1 (0.68) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL1059581 | 0.73 | NUDT1 (0.68) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL17440085 | 0.72 | ADORA2A (0.49) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL843169 | 0.72 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| EP-2915815-B1 | NEW MODIFIED NUCLEIC ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| US-9156874-B2 | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-10-13 | — | — | US | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-9095599-B2 | O-(substituted benzyl) phosphoramidate compounds and therapeutic use | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-08-04 | — | — | US | disclosed |
| US-20140038916-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | NANJING MOLECULAR RESEARCH, INC. (CN) | 2014-02-06 | — | — | US | disclosed |
| WO-2013187978-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-08-15 | — | — | US | disclosed |
| WO-2012094248-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | NANJING MOLECULAR RESEARCH, INC. (CN) | 2012-07-12 | — | — | WO | disclosed |
| US-7585851-B2 | 3′-prodrugs of 2′-deoxy-β-L-nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038916-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | PNP, PAICS, TYMP | ADORA2A 235/4885ADORA1 238/4885NUDT1 6/4885 |
| US-20160016983-A1 | New Modified Nucleic Acid | RNGTT, RNASEH1, RNASE1 | ADORA2A 299/4885ADORA1 360/4885NUDT1 202/4885 |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | PNP, PAICS, NTPCR | ADORA2A 68/4885ADORA1 74/4885NUDT1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.